FMP
Flexion Therapeutics, Inc.
FLXN
NASDAQ
Inactive Equity
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
9.12 USD
0 (0%)
About
ceo
Dr. Michael Clayman
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
http://www.flexiontherapeutics.com
exchange
NASDAQ
Description
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
CIK
0001419600
ISIN
US33938J1060
CUSIP
33938J106
Address
10 Mall Rd Ste 301
Phone
17813057777
Country
US
Employee
257
IPO Date
Feb 12, 2014
Key Executives
